EVIDENCE MATRIX / FOUR FILES
Compare the Claim, the Study, and the Gap
GHK-Cu, KPV, semaglutide, and tirzepatide share a broad label. Their mechanisms, study settings, and burdens of proof are sharply different.
In plain English
A fair comparison begins by refusing the easiest comparison. These four compounds cannot be ranked on one scale called “best peptide.” They were built for different jobs and tested in different ways. GHK-Cu is a copper-binding cosmetic and research peptide with limited topical human work. KPV is an anti-inflammatory fragment supported by cell and mouse studies. Semaglutide and tirzepatide are prescription incretin drugs backed by randomized human trials.
The useful questions are narrower. What molecular target does each engage? Did the evidence come from a cell dish, an animal, a small topical study, or a large outcome trial? Does a reported experience match a measured endpoint? What remains unknown? On those terms, semaglutide and tirzepatide have the most mature human evidence, while KPV has the largest translation gap. GHK-Cu occupies the middle: suggestive topical data with delivery and replication limits. The table is a map of evidence type, not a treatment ranking.
The evidence matrix
| Compound | Main target or action | Strongest evidence in this file | Evidence maturity | Central gap |
|---|---|---|---|---|
| GHK-Cu | Copper carriage; skin-matrix and signaling effects | Reviews of small topical human studies, a combination hair trial, and ex vivo skin penetration [1][3][5] | Limited human topical evidence plus laboratory work | Delivery, independent replication, and no validated systemic human evidence |
| KPV | PepT1 uptake; suppression of NF-kB and MAP-kinase inflammatory signaling | Cultured cells, mouse colitis models, and targeted nanoparticle studies [6][7][8][9] | Preclinical | No published human clinical trials in the supplied record |
| Semaglutide | Selective GLP-1 receptor agonism | Large randomized weight, cardiovascular, kidney, and diabetes outcome trials [12][13][14][17] | Mature clinical and regulatory evidence | Tolerability, long-term management, and unresolved low-incidence safety signals |
| Tirzepatide | Dual GIP and GLP-1 receptor agonism | Randomized obesity and diabetes trials, including direct comparison with semaglutide [11][20][21] | Mature clinical and regulatory evidence | Long-term comparative outcomes, tolerability, and biliary risk |
Mechanism: four different verbs
GHK-Cu carries copper and appears to influence matrix-producing cells and broad gene-expression programs [2][4]. KPV dampens inflammatory signaling in experimental systems and uses a short-peptide transporter in inflamed intestinal tissue [8][10]. Semaglutide activates GLP-1 receptors involved in glucose control, appetite, and gastric emptying, with animal mapping supporting distributed brain pathways [16]. Tirzepatide combines GIP and GLP-1 receptor activation in one peptide [18].
Those verbs describe biological actions. They do not convey evidence maturity. GHK-Cu’s wide transcriptomic signal does not place it above a large cardiovascular outcome trial. KPV’s targeted colon delivery does not establish a human gut-health benefit. Conversely, regulatory approval does not mean every mechanistic claim about semaglutide or tirzepatide has been proven. The discipline is to let mechanism explain why a result might occur while allowing the experiment to determine whether it did.
Studies versus reports
All community experiences summarized here are anecdotal, not clinical evidence. GHK-Cu users commonly describe cosmetic changes in firmness, hydration, texture, or irritation. Semaglutide and tirzepatide communities often describe reduced food preoccupation, earlier fullness, weight change, gastrointestinal symptoms, fatigue, and occasional hair shedding. The KPV source file contains no composed real-world signals, so this digest does not manufacture a list.
The overlap between a report and a known mechanism can make the report more plausible, but not more controlled. Slower gastric emptying offers a credible explanation for nausea or fullness with incretin drugs; it cannot establish that a particular post caused by the drug or show how common the experience is. Likewise, a skin-matrix mechanism does not authenticate a before-and-after photograph. Reports are most useful as signals: they can identify language patients use, overlooked tolerability issues, and questions for prospective study. They remain a different evidence stream.
What the strongest comparisons actually say
Only semaglutide and tirzepatide can be compared directly on a shared human trial endpoint in this corpus. SURMOUNT-5 found greater mean weight loss with tirzepatide than semaglutide over seventy-two weeks in adults with obesity but without diabetes [11]. SURPASS-2 found greater glucose and weight reductions with tirzepatide than the studied semaglutide comparator in adults with type 2 diabetes [21]. Those results support a comparative efficacy statement within those settings. They do not make tirzepatide superior for every outcome. Semaglutide’s separate cardiovascular and kidney trials answer questions not answered by a weight-only comparison [12][13].
GHK-Cu and KPV should not be pulled into that league table. Their endpoints, routes, and development stages are different. The most honest cross-member conclusion is therefore about evidence architecture: large randomized human outcomes carry more direct clinical weight than small topical studies, which carry more direct human relevance than animal or cell findings. Each layer can be informative. None should masquerade as another.